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Abstract
Background/Aims: Liver stiffness (LS) measurement by means of transient elastography (TE) is accurate to predict fibrosis
stage. The effect of antiviral treatment and virologic response on LS was assessed and compared with untreated patients
with chronic hepatitis C (CHC).
Methods: TE was performed at baseline, and at weeks 24, 48, and 72 in 515 patients with CHC.
Results: 323 treated (62.7%) and 192 untreated patients (37.3%) were assessed. LS experienced a significant decline in
treated patients and remained stable in untreated patients at the end of study (P,0.0001). The decline was significant for
patients with baseline LS$ 7.1 kPa (P,0.0001 and P 0.03, for LS$9.5 and$7.1 kPa vs lower values, respectively). Sustained
virological responders and relapsers had a significant LS improvement whereas a trend was observed in nonresponders
(mean percent change 216%, 210% and 22%, for SVR, RR and NR, respectively, P 0.03 for SVR vs NR). In multivariate
analysis, high baseline LS (P,0.0001) and ALT levels, antiviral therapy and non-1 genotype were independent predictors of
LS improvement.
Conclusions: LS decreases during and after antiviral treatment in patients with CHC. The decrease is significant in sustained
responders and relapsers (particularly in those with high baseline LS) and suggests an improvement in liver damage.
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Introduction
Liver fibrosis is a key determinant of morbidity and mortality in
the natural history of CHC. There is evidence that antiviral
therapy can improve liver histology not only by reversing liver
damage in sustained responders, but also by slowing the
progression in relapser patients. [1,2].
Liver biopsy has been currently considered the reference
standard to assess the extent of fibrosis, though it is associated
with risk of complications and has limitations due to observer
variability and sampling error.[3–5] Thus, several routine
laboratory tests combined in scores and indices such as Forns’
score, APRI index and FIB-4 index, [6–9] or other panels like
FibroTest (a2-macroglobulin, haptoglobin, apolipoprotein A1,
gammaglutamyl transpeptidase and total bilirubin) [10] and more
recently the ELF score (aminoterminal propeptide of type III
procollagen (PIIINP), hyaluronic acid (HA) and tissue inhibitor of
matrix metalloproteinase type 1 (TIMP-1)) [11] have been
validated as useful tools to accurately detect significant fibrosis
or cirrhosis in clinical practice. FibroTest, ELF score, Forns Score
or other tests that include markers of extracellular matrix have
been also validated in the evaluation of response to interferon-
based therapy. [12–15].
More recently, transient elastography has emerged as a useful,
rapid and reproducible tool to measure liver stiffness as an
accurate marker to predict liver fibrosis degree.[16–20] Further-
more, the utility of elastography has also been evaluated in
monitoring progression of fibrosis in the setting of hepatitis C virus
recurrence after liver transplantation. [21].
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In addition, changes in liver stiffness both during and after
antiviral treatment have been previously examined by several
other studies.[22–24].
The aims of this large prospective longitudinal multicentre study
were to assess the effects of antiviral treatment and virologic
response in liver stiffness and compare these changes with
untreated patients with CHC. In addition, other biochemical
and indirect tests of liver fibrosis were also assessed.
Patients and Methods
Ethics Statement
All patients provided written informed consent for blood
samples and to data handling in accordance with a protocol
specifically approved by the appropriate institutional review
boards (IRB) which included: Hospital Clinic of Barcelona IRB
and University Hospital of Bordeaux IRB for the centers in
France.
Study Population
From July 2008 through March 2009, we conducted this
prospective multicentre study at ten participating sites in three
European countries (Spain, France and Italy).
A total of 515 consecutive patients with CHC were enrolled in
this study. The diagnosis of CHC was established by the presence
of hepatitis C virus (HCV) RNA using polymerase chain reaction
assays. Patients with human immunodeficiency virus or hepatitis B
virus co-infection, or with other causes of chronic liver disease
were not included.
Transient Elastography
Liver stiffness measurement was performed using transient
elastography (FibroScan, Echosens, Paris France) by the previously
described technique. Briefly, with the patient lying in dorsal
decubitus with the right arm at maximal abduction, a transducer
probe on the axis of a vibrator is placed on the skin, between the
rib bones at the level of the right lobe of the liver. Mild amplitude
and low-frequency vibrations (50 Hz) are transmitted to the liver
tissue, inducing an elastic shear wave that propagates through the
underlying liver tissue. The operator in each center was a nurse
who had previously performed at least 100 determinations in
patients with chronic liver disease and who was unaware of
patients status. Ten successful measurements were performed on
each patient and the success rate was calculated as the number of
validated measurements divided by the total number of measure-
ments. The results were expressed in kilopascals (kPa). The median
value of successful measurements was considered representative of
the liver stiffness in a given patient, according to the manufactur-
er’s recommendations (interquartile range (IQR) less than 30% of
the median value and success rate .60%). [25,26].
Serum Fibrosis Marker Panels
Blood samples were collected at baseline and during the study at
weeks 24, 48 and 72. Laboratory tests included complete blood cell
counts, HCV RNA serum concentration, HCV genotype,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), gamma glutamyl transpeptidase (GGT) and cholesterol.
Marker panels of fibrosis including APRI and FIB-4 index were
calculated as previously described.[7–9].
Liver Histology
Indication of a liver biopsy was not mandatory in treated or
untreated patients. It was offered to individuals as part of the
evaluation for diagnosis and prognosis of the disease, in the setting
of routine clinical practice in each center, independently of the
final treatment decision. Percutaneous liver biopsies were
performed under local anesthesia and ultrasound guidance with
a Tru-Cut 14 gauge needle (Angiomed, Bard, Karlsruhe,
Germany). Specimens were fixed in formalin, embedded in
paraffin and stained with hematoxylin-eosin and Massons
trichrome. A minimum length of 10 mm and the presence of 6
portal tracts were required for diagnosis. Histological grade and
stage were determined according to METAVIR scoring system
[27] by a pathologist who was blinded for patients’ data. Liver
fibrosis was considered significant when it spread out of the portal
tract (stages 2, 3 or 4).
Study Protocol
Treated patients included those who had stiffness values higher
than 7.1 kPa (less likely to have absent or mild fibrosis according to
previously suggested cut-off) [16] and those who wanted to receive
antiviral treatment independent of their low liver stiffness values.
Patients with stiffness values below 7.1 kPa or those who refused or
had a contraindication for antiviral treatment remained untreated.
Liver stiffness measurements were obtained at baseline and at
weeks 24, 48 (end of treatment) and 72 (end of follow-up) for G1-
infected patients and at baseline and weeks 24 and 48 for G2/3-
infected patients.
Treatment
Antiviral treatment was the standard of care, with weekly
pegylated interferon alfa-2a (180 ug) or alfa-2b (1.5 ug/kg) plus
ribavirin (0.8–1.2 g daily) for 24 or 48 weeks, according to HCV
genotype. The use of hematopoietic growth factors, epoetin alfa or
darbepoetin and filgrastim, was allowed to treat anemia or
neutropenia, respectively. Sustained virologic response (SVR) was
defined by undetectable serum HCV RNA by qualitative
polymerase chain reaction assay (Cobas Amplicor, HCV Roche,
Branchburg, New Jersey, USA; v 2.0, detection limit 50 IU/mL) at
24 weeks after the end of therapy. According to stopping and
futility rules, patients with a decrease of HCV RNA level ,2 log10
IU at week 12 or a detectable HCV RNA at 24 weeks were
considered to have treatment failure, and therapy was discontin-
ued.
Statistical Analysis
Descriptive values are expressed as percentages and the mean
(6SD) or median (range). Quantitative data were compared using
Students t-test or the non-parametric Mann–Whitney rank-sum
test, as appropriate. The Chi-square test was used to evaluate
categorical variables. The odds ratio, together with its 95%
confidence interval (CI) and the corresponding P-value, was
calculated for relative risks by using logistic regression. P values
below 0.05 were considered statistically significant. The Wilcoxon
matched pairs signed-rank test was used to evaluate changes
between baseline and end of follow-up evaluations. To test for any
associations with liver stiffness improvement, defined as a decrease
of 20% or more from baseline LS values, variables with a P value
of less than 0.1 on univariate testing were entered into a
multivariate regression analysis. The Pearson’s correlation coeffi-
cient was used to analyse the correlations between values of liver
elastography and ALT, FIB-4 index and APRI. The general linear
model (GLM) for analyzing repeated measures technique was used
to examine the changes of liver stiffness over time. All statistical
analyses were performed with SPSS software (version 16.0, SPSS
Inc, Chicago, IL).
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Results
Baseline clinical, laboratory and virologic characteristics of the
patients are shown in Table 1. A total of 515 patients were
evaluated: 323 treated patients (62.7%) and 192 untreated patients
(37.3%). The mean age of the treated patients was 48.5 years, 66%
were male and 56.7% were infected with HCV genotype 1. The
mean age of untreated patients was 53.9 years, 35.9% were male
and the vast majority (76.6%) were infected with HCV genotype 1.
Treated patients had significantly higher baseline levels of serum
ALT, AST and GGT, as well as higher histologic activity and
fibrosis.
Baseline Comparison of Liver Stiffness
Treated patients had significantly higher baseline LS than
untreated patients (10.668.9 and 5.962.7, respectively,
P,0.0001). Liver biopsies were carried out in 319 patients (189
patients in the treatment cohort). The stage of liver fibrosis was
distributed as follows: F0, n= 45 (14.1%); F1, n= 112 (35.1%); F2,
n = 101 (31.7%); F3, n= 26 (8.2%); F4, n= 35 (11%). The
prevalence of significant fibrosis (F$2) in this cohort was 50.9%.
The areas under the receiver operating characteristic (ROC) curve
of the FibroScan were 0.70 (95%CI, 0.62–0.74), 0.86 (95%CI,
0.81–0.92) and 0.87 (0.95%CI, 0.80–0.94), for F$2, F$3 and
F= 4, respectively. Areas under ROC curve of APRI and FIB4
were 0.70 (95%CI, 0.63–0.75) and 0.65 (95%CI, 0.60–0.71), 0.78
(95% CI 0.72–0.85) and 0.70 (95%CI, 0.60–0.80), 0.80 (95%CI,
0.71–0.90) and 0.70 (95%CI,0.60–0.80), for F$2, F$3 and F= 4,
respectively.
Changes in Liver Stiffness during Treatment and
According to Virologic Response
Mean liver stiffness values at each study time point for untreated
and treated patients are shown in Table 2. After antiviral
treatment, 202 patients (62.5%) achieved a sustained virologic
response, while 121 patients (37.4%) did not. Among the latter, 66
patients (20.4%) had undetectable HCV-RNA at the end of
treatment but then relapsed during follow-up. The mean interval
between baseline elastography and end of study was 521.06185.3
and 734.7683.0 days for treated and untreated patients,
respectively (P,0.0001).
A significant decrease in LS values was observed only in treated
patients whereas in untreated patients these measurements
remained stable from basal assessment to the end of the study
period (P,0.0001). The LS dynamic profile of treated versus
untreated patients is shown in Figure 1, and is based on the GLM
repeated measures analytical approach (P,0.0001).
The evolution of liver stiffness according to treatment and
virologic response and the mean percentage of change over time in
the 72-week period are shown in Table S1 (supporting material)
and Figure 2, respectively. The dynamic profile according to
virologic response is shown in Figure S1 (supplementary material).
Table 1. Baseline characteristics of the patients.
Variable Antiviral treatment cohort Untreated P value
n=323 n=192
Age (yrs) 48.5611.2 53.9611.7 ,0.001
Sex (male) 214 (66.3) 69 (35.9) ,0.001
Body mass index (kg/m2 ) 24.663.4 23.463.3 0.07
AST/ULN 1.961.4 1.160.6 ,0.001
ALT/ULN 2.762.7 1.461.1 ,0.001
GGT/ULN 1.561.4 1.261.1 0.001
Platelet count (103/mm3) 206.6667.6 239.6655.9 ,0.001
HCV RNA log10 (IU/mL) 5.860.9 5.860.8 0.5
HCV genotype ,0.001
1 186 (57.6) 147 (76.6)
2 41 (12.7) 20 (10.4)
3 76 (23.5) 9 (4.7.)
4 17 (5.3) 13 (6.8)
Other 3 (0.9) 3 (1.5)
Fibrosis stage n=189 n=130 ,0.001
F 0–1 78 (41.3) 79 (60.8)
F 2 60 (31.7) 41 (31.5)
F 3 19 (10.1) 7 (5.4)
F 4 32 (16.9) 3 (2.3)
Histologic activity 0.05
A 0–1 123 (65.1) 97 (74.5)
A 2 58 (30.7) 31 (24)
A 3 8 (4.2) 2 (1.6)
Results are expressed as the mean 6 standard deviation or n (%).
ULN, upper limit of normal.
doi:10.1371/journal.pone.0047715.t001
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Compared with baseline, a significant reduction in liver stiffness
was experienced by treated patients versus untreated (mean
percentage change 212% vs 3%, P,0.0001). This decline was
statistically significant for those patients with baseline LS $
7.1 kPa versus those below this cut-off value (mean percent
changes 222%, P,0.0001 and 218%, P 0.03, for baseline LS
$9.5 kPa and$7.1 kPa, respectively). In the analysis according to
the final virologic response, the baseline LS in sustained
responders was significantly lower than in relapser responder
and nonresponder patients (P 0.006). At week 24 and 48 all treated
patients (sustained virological responders, relapsers and nonre-
sponders) had significant LS decreases from baseline, with no
different mean percentage changes between them. However, only
sustained and relapser responders had a significant LS improve-
ment at the end of study,(mean percentage change 216%, 210%
and 22, for SVR, RR and NR, respectively, P 0.03 for SVR vs
NR).
Among the 110 treated patients with baseline liver stiffness
above the cut-off for advanced fibrosis and cirrhosis, values
decreased below the cut-off level in 52 (47%) of them; interestingly
the majority of them (70%) were sustained virological responders
(Figure 3). The mean percent change in the sustained responders
with LS values above cut-off for prediction of F3 (9.5 kPa) and F4
(12.5 kPa) was 225.5% and 230.8%, which resulted in a change
to a lower stage of fibrosis in 80 and 60% of them, respectively.
ALT, AST and GGT serum values and FIB 4 index and APRI
calculations had a significant correlation with LS at baseline
(r = 0.33, 0.47, 0.34, 0.5, 0.6, respectively, P 0.0001). Similarly,
ALT, FIB-4 index and APRI determinations demonstrated the
evolution of LS according to treatment and virologic response,
with significant differences at the end of study between SVR vs
NR and RR (P,0.001). Serum ALT correlated significantly with
LS in each time point of the study for each group of virologic
response except for relapsers at 24 weeks post- therapy, where
ALT (but not LS) showed a rebound (Figure S 1 B, supporting
material).
Predictors of Liver Stiffness Improvement
By univariate analysis, the following variables were associated
with liver stiffness decline: male gender, low platelet count and
time of follow-up, high body weight, body mass index (BMI), AST,
Table 2. Liver stiffness variations during study and after follow-up and according to virologic response.
FibroScan (kPa) Baseline 24 weeks P 48weeks or EOTe P
72 weeks or 24 weeks
of follow upe P
Treated 10.668.9¤ 9.067.2 ,0.001 8.867.0 ,0.001 8.566.6 ,0.001
SVR 9.365.9* 7.764.1 ,0.001 7.764.7 ,0.001 7.464.4 ,0.001
RR 12.9612.9* 11.469.9 0.009 10.969.5 0.01 10.168.7 ,0.001
NR 12.4611.3* 11610.2 0.001 10.6610.2 0.02 11.369.1 0.05
Untreated 5.962.7¤ 6.363.4 0.3 663.3 0.8 663.2 0.7
Results are expressed as the mean.
*P 0.006 SVR vs RR and NR.
¤P,0.0001.
efor untreated or treated patients, respectively.
doi:10.1371/journal.pone.0047715.t002
Figure 1. Liver stiffness evolution in treated vs untreated
patients: Significant changes over time in treated vs untreated
patients.
doi:10.1371/journal.pone.0047715.g001
Figure 2. Mean percentage of change in liver stiffness from
baseline to end of study according to treatment and virologic
response.
doi:10.1371/journal.pone.0047715.g002
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ALT, GGT, histologic activity, baseline LS values, non-1
genotype, diabetes and antiviral treatment. In the final model of
multivariate analysis, baseline higher LS values (odds ratio (OR)
1.14, 95% CI 1.0–1.2, P,0.0001), ALT levels (OR 1.0, 95%CI
1.001–1.009, P= 0.01), antiviral therapy (OR 0.5, 95%CI 0.3–0.9,
P=0.003) and non-1 genotype (OR 1.06, 95%CI 0.4–1, P=0.03)
were independent predictors of LS improvement (Table 3).
Discussion
The primary aim of this study was to assess liver stiffness
changes following treatment with pegylated interferon and
ribavirin. The results demonstrate a significant stiffness decrease
with antiviral treatment in comparison with untreated patients.
According to the type of response, significant changes were
detected only in sustained responders and relapsers. Previous
studies had also shown a significant decrease in liver stiffness values
in sustained responders.[22–24].
The improvement in liver stiffness at the end of study was
particularly notable for those patients with higher pre-treatment
liver stiffness values. As expected, two of the independent baseline
predictors of the improvement were LS and ALT levels. The good
correlation between LS and serum ALT levels during and after
antiviral therapy, at least for sustained responders, as well as the
association of LS improvement with ALT levels at baseline, is
consistent with previous studies in which liver stiffness dynamic
profiles ran in parallel with serum ALT in patients with CHC or in
the course of acute hepatitis. [28,29] Although ALT has some
association with inflammatory activity in the liver, its association
with variations in stiffness may reflect, to some extent, the
influence of necroinflammatory changes on LS measurements, as
was shown in the study by Fraquelli. [30] Moreover, according to
Figure 3. Liver stiffness evolution in patients with measurements above the cut-off value for advanced fibrosis and cirrhosis
according to virologic response. The y axis is in logarithmic scale. The black dots indicate the mean liver stiffness value at each time points.
doi:10.1371/journal.pone.0047715.g003
Table 3. Factors associated with liver stiffness improvement.
Univariate analysis Multivariate analysis
Variables Odds ratio 95% CI P Odds ratio 95% CI P
Male gender 1.54 0.08–2.7 0.01
BMI#25 Kg/m2 0.9 0.5–1.7 0.03
Diabetes 0.6 0.2–2.2 0.001
Genotype 1 0.6 0.4–0.9 0.004 0.6 0.4–1.0 0.03
Antiviral treatment 0.4 0.2–0.7 ,0.001 0.5 0.3–0.8 0.003
Time between TE and end of FU 1 0.9–1 0.02
Weight 1.02 0.9–1.0 0.01
Platelet count 1 0.9–1 0.05
AST 1 1.0–1.02 ,0.001
ALT 1.5 1.00–2.0 ,0.001 1.005 1.0–1.01 0.01
GGT 1.0 0.8–1.2 0.001
Liver stiffness 1.2 1.1–1.2 ,0.001 1.14 1.0–1.2 ,0.001
Histologic activity 1.6 0.9–2–8 0.08
BMI, body mass index; FU, follow-up.
doi:10.1371/journal.pone.0047715.t003
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univariate analysis, the histologic activity was also associated with
stiffness improvement. The lack of correlation between liver
stiffness and ALT at the follow-up measurement in the group of
relapser patients might suggest that ALT changes are seen earlier
than liver stiffness, which may more directly reflect necroin-
flammation/edema of reactivation once antiviral pressure is
withdrawn.
The fact that nearly 50% of the patients with LS values above
the cut-off for advanced fibrosis decreased to values of non-
advanced fibrosis at follow-up may be in agreement with previous
studies that demonstrate liver fibrosis regression by histological
parameters in concordance with noninvasive tests assessment of
fibrosis degree in patients receiving interferon-based therapy.
[1,2,31] These results were even more striking in the subset of
sustained virological responders, with a reduction of the predicted
fibrosis stage in 80% and 60% of patients who had at baseline an
estimated F3 and F4 according to the proposed cut-offs values,
respectively. Indeed, the decrease in LS values in patients who
achieved SVR were higher than 20% of baseline levels in a
significant proportion of individuals with advanced liver fibrosis.
The fact that stiffness decrease remained significant at follow-up
only in sustained responders and relapsers may suggest its
association with liver fibrosis regression.
Our study has some limitations. First, accuracy to diagnose
significant fibrosis was lower than in other published reports. Since
the study was not specifically designed to assess the performance of
FS to evaluate liver fibrosis, the lower accuracy value may partially
reflect ‘‘real-life’’ problems in diagnostic performance (liver
biopsies were not evaluated by a single pathologist, biopsies not
reaching a minimum desirable length might have been included).
Nevertheless, accuracy to diagnose advance fibrosis and cirrhosis
was excellent. A second limitation is that at any conclusions are
necessarily constrained by the lack of available liver biopsies to
definitively confirm their degree of regression at follow-up. Thus,
based on our results and on previous observations, confounders
other than liver fibrosis, mainly inflammatory activity, may
partially influence these findings. A final limitation of our study
is the short time of follow-up of patients, which may explain
similar LS dynamics between sustained responders and relapsers,
and no increase in LS values in untreated patients. Strengths of the
current study were the large number of CHC patients enrolled
from multiple centers who received the same combination antiviral
therapy in a prospective study.
In summary, this study of a large cohort of patients with CHC
confirms that a significant improvement in LS is associated with
antiviral therapy in sustained responders and relapsers. Further
evaluation of transient elastography in the long- term follow-up of
changes in liver fibrosis in these patients is needed.
Supporting Information
Figure S1 Liver stiffness and serum ALT at weeks 24, 48
and 72, as compared with baseline, according to
virologic response. (A) Liver stiffness. (B) Serum ALT.
(TIF)
Table S1 Liver stiffness, APRI, FIB-4 index and ALT
evolution (mean delta change) from baseline to end of
study.
(DOC)
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